Don't let it get away!
Keep track of the stocks that matter to you.
Help yourself with the Fool's FREE and easy new watchlist service today.
From cutting edge science to the impact of Obamacare, from clinical trial results to FDA decisions, and from Bieber fever to hay fever, The Motley Fool's health-care team sits down each week to discuss the most fascinating developments across the health-care industry and their implications for long-term investors. In this week's edition, the team talks about an exciting drug approval, how computers can help scientists develop new drugs, and stocks that have both soared and crashed. The analysts close with a discussion of companies that they'll be closely following in the coming weeks.
In the segment below, health-care analyst Max Macaluso discusses the upcoming FDA decision regarding Johnson & Johnson's (NYSE: JNJ ) type 2 diabetes drug Invokana, and how the regulatory agency's opinion could be shaped by a previous rejection of a similar drug developed by Bristol-Myers Squibb (NYSE: BMY ) and AstraZeneca (NYSE: AZN ) .
Is bigger really better?
Involved in everything from baby powder to biotech, Johnson & Johnson's critics are convinced that the company is spread way too thin. If you want to know if J&J is nothing but a bloated corporate whale -- or a well-diversified giant that's perfect for your portfolio -- check out the Fool's new premium report outlining the Johnson & Johnson story in terms that any investor can understand. Claim your copy by clicking here now.
The relevant video segment can be found between 2:39 and 4:15.